Emerging Agents for T790M-Mutant Patients With NSCLC

June 7, 2016
Howard L. (Jack) West, MD

Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses emerging agents on the horizon for patients with T790M-mutant patients with non-small cell lung cancer.